322
Views
15
CrossRef citations to date
0
Altmetric
Research Articles

Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: A five-year follow-up study

, , , , , , , , , , , , , , & show all
Pages 548-555 | Received 29 Jan 2014, Accepted 22 Jun 2014, Published online: 21 Jul 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Laurence Du Pasquier-Fediaevsky, Stefan Andrei, Michel Berche, Laurence Leenhardt, Emmanuel Héron & Sébastien Rivière. (2019) Low-Dose Rituximab for Active Moderate to Severe Graves’ Orbitopathy Resistant to Conventional Treatment. Ocular Immunology and Inflammation 27:5, pages 844-850.
Read now

Articles from other publishers (14)

Naiara F. Xavier, Daniela Tavares Lucena & Antonio A. V. Cruz. (2023) Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. Ophthalmic Plastic & Reconstructive Surgery 39:4, pages 307-315.
Crossref
Diane Giovannini, Aude Belbezier, Athan Baillet, Laurence Bouillet, Mitsuhiro Kawano, Chantal Dumestre-Perard, Giovanna Clavarino, Johan Noble, Jacques-Olivier Pers, Nathalie Sturm & Bertrand Huard. (2023) Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues. Frontiers in Immunology 14.
Crossref
Yueyue Wang, Hao Hu, Lu Chen, Haitao Zhang, Tao Yang, Xiaoquan Xu & Huanhuan Chen. (2023) Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study. Frontiers in Endocrinology 13.
Crossref
Irene Campi, Guia Vannucchi, Ilaria Muller, Elisa Lazzaroni, Nicola Currò, Martina Dainese, Benedetta Montacchini, Danila Covelli, Claudio Guastella, Lorenzo Pignataro, Laura Fugazzola, Maura Arosio & Mario Salvi. (2022) Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy. Frontiers in Endocrinology 12.
Crossref
Jing Chen, Gang Chen & Huilan Sun. (2021) Intravenous rituximab therapy for active Graves’ ophthalmopathy: a meta-analysis. Hormones 20:2, pages 279-286.
Crossref
Mario Salvi & Danila Covelli. (2018) B cells in Graves’ Orbitopathy: more than just a source of antibodies?. Eye 33:2, pages 230-234.
Crossref
Changjun Wang, Qingyao Ning, Kai Jin, Jiajun Xie & Juan Ye. (2018) Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmology 18:1.
Crossref
Fotini Adamidou, Panagiotis Anagnostis, Kostas Boboridis, Christina Manani, Thomas Georgiou, Stavroula Veneti & Marina Kita. (2018) Enduring remission of active and sight-threatening Graves’ orbitopathy with rituximab: report of two cases. Endocrine Journal 65:9, pages 963-967.
Crossref
Niels-Peter Becker, Johannes Müller, Peter Göttel, Gerd Wallukat & Ingolf Schimke. (2017) Cardiomyopathy — An approach to the autoimmune background. Autoimmunity Reviews 16:3, pages 269-286.
Crossref
Flavien Précausta, Sophie Arsène, Peggy Renoult-Pierre, Boris Laure, Lise Crinière & Pierre-Jean Pisella. (2017) Treatment by rituximab on six Grave's ophthalmopathies resistant to corticosteroids. Annales d'Endocrinologie 78:1, pages 20-26.
Crossref
Jason Ellis & Helen Braley-Mullen. (2017) Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases. Journal of Clinical Medicine 6:2, pages 13.
Crossref
J. Müller, G. Wallukat & I. Schimke. 2017. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases 659 679 .
Irene Campi, Guia Vannucchi & Mario Salvi. (2016) THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves’ orbitopathy. European Journal of Endocrinology 175:3, pages R117-R133.
Crossref
Miriam Ladsous. (2016) Therapeutic innovations in endocrine diseases – Part 5: Rituximab and graves’ orbitopathy. La Presse Médicale 45:6, pages e221-e224.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.